Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Shareholders held by TriSalus Life Sciences, Inc. on June 12, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Westminster, Colorado.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Shareholder participation was significant, with 26,482,799 shares (73.2% of the 36,180,828 outstanding shares as of the April 17, 2025 record date) represented at the meeting. The following matters were approved:
- Election of Directors: Two nominees were elected to three-year terms expiring in 2028:
- Mats Wahlström: 20,002,109 votes For; 501,937 Abstain; 5,978,753 Broker Non-Votes.
- David J. Matlin: 20,005,151 votes For; 498,895 Abstain; 5,978,753 Broker Non-Votes.
- Ratification of Auditors: The appointment of Grant Thornton, LLP as the independent registered accounting firm for 2025 was ratified with 26,445,528 votes For, 36,277 Against, and 994 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the new three-year terms for directors Mats Wahlström and David J. Matlin.
- Confirm the engagement of Grant Thornton, LLP as the independent auditor for the 2025 fiscal year.
- Review the high volume of broker non-votes (approx. 5.98 million) regarding director elections to understand potential proxy voting dynamics.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.